Fig. 1From: The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case reportChanges of EGFR mutations (copies/ml) in ctDNA of patient during treatments. PR: partial response; SD: stable disease; PD progressive disease. The numbers before the year indicate the monthsBack to article page